hyoscine-n-butyl bromide
Endometrial Cancer
Centre de recherche du Centre hospitalier universitaire de SherbrookeSmall moleculePhase 1/2Dormant
CC
44/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 65/ 100
Competitive context
234 Active assets in the Endometrial Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Indocyanine Green Istanbul University | Phase 4 | BB |
Inno-206 AstraZeneca | Phase 3 | BB |
Olaparib Qilu Pharmaceutical Co., Ltd. | Phase 4 | BB |
Palbociclib University Medical Center Groningen | Phase 4 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | B |
View all 50 →
Same molecule, other indications
hyoscine-n-butyl bromide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →